ADCC News and Research

RSS

Spike-induced humoral immunity and its association with antibody-dependent cellular cytotoxicity potency

A new study aimed to analyze the qualitative and quantitative impact of S-induced humoral immunity along with its ADCC capability in individuals who received a vaccination, recovered from an infection, or both.

14 Mar 2023

Clec9A-RBD immunization could trigger robust and sustained systemic and mucosal immune responses against rapidly evolving SARS-CoV-2 variants

Researchers assessed the impact of a single-dose dendritic cell vaccine candidate on immune responses against SARS-CoV-2.

23 Feb 2023

Researcher contextualizes a study on IgG4 anti-Spike levels after repeated SARS-CoV-2 mRNA vaccination

A researchers emphasized the need to reconsider mRNA COVID-19 vaccination strategies in the future,

9 Feb 2023

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

Researchers explored how mutations in emergent SARS-CoV-2 variants affect viral function, human immunity, and recognition by therapeutic antibodies.

19 Jan 2023

The binding and functional serologic responses to COVID-19 vaccination in children with history of MIS-C

Researchers evaluated the serological responses elicited by COVID-19 vaccinations in children who developed MIS-C following a previous SARS-CoV-2 infection.

23 Nov 2022

New method for isolating Omicron subvariant and evaluating resistance to therapeutic and vaccine-elicited antibodies

Researchers demonstrated a viral amplification procedure to isolate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants.

21 Nov 2022

The impact of seasonal coronavirus immunity on susceptibility to SARS-CoV-2 infection and COVID-19 vaccination

Researchers investigated whether immunity against seasonal human coronavirus spike proteins of HKU1, OC43, NL63, or 229E could protect against SARS-CoV-2 in vitro.

28 Oct 2022

Researchers design a COVID-19 vaccine construct using hybrid SARS-CoV-2 spike protein and nucleocapsid protein peptides

Researchers designed a COVID-19 vaccine construct using hybrid SARS-CoV-2 S protein (containing SARS-CoV-2 Delta and Omicron variant mutations) and N protein peptides that confer T lymphocyte-mediated immune protection.

25 Oct 2022

Vaccine-induced neutralizing and non-neutralizing antibody activity against SARS-CoV-2

A new study demonstrated that vaccine-induced antibody functions against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diminish with age.

7 Oct 2022

Vaccination drives superior functional antibody breadth compared to natural infection with SARS-CoV-2

Researchers assessed the potency and breadth of antibody recognition and effector function among healthy and high-risk individuals following natural SARS-CoV-2 infection or mRNA COVID-19 vaccination.

21 Sep 2022

Alternative approaches to functional and phenotypic assays using multi-parameter flow cytometry

Synexa is an industry-leading biomarker and large molecule bio analytic research service provider. In this interview, NewsMedical speaks with Natalie Strickland, a principal scientist at Synexa, about alternative approaches to flow cytometry.

From Synexa Life Sciences BV 5 Sep 2022

The efficacy of therapeutic monoclonal antibodies and serum from monoclonal antibody-treated patients against Omicron sublineages

Researchers evaluated the neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 sub-variants by therapeutic monoclonal antibodies.

16 Aug 2022

The identification and characterization of an anti-SARS-CoV-2 monoclonal antibody with superior breadth and potency

A recent study published in Nature Microbiology identified a monoclonal antibody neutralizing SARS-CoV-2 Omicron variants.

28 Jul 2022

High-level resistance of SARS-CoV-2 BA.4 against neutralizing antibodies

Researchers evaluates the sensitivity of BA.4 in both vaccinated and unvaccinated individuals infected with the SARS-CoV-2 variants.

20 Jul 2022

Immunoglobulin G isotypes switch class following repeated SARS-CoV-2 mRNA vaccination

Researchers reported a class switch in SARS-CoV-2-specific antibodies due to repeated mRNA vaccinations.

13 Jul 2022

Scientists investigate impact of SARS-CoV-2 RBD mutations across variants

In a recent study posted to the medRxiv* pre-print server, Australian researchers comprehensively investigated the impact of 39 receptor-binding-domain (RBD) mutations in six severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) and variants of interest (VOIs).

12 Jul 2022

Patient-derived antibody cocktail active across SARS-CoV-2 variants of concern

In a recent study published in the journal Science Immunology, researchers in the United States described a rare anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) three antibody cocktail IMM-BCP-01.

4 Jul 2022

Fc-effector functions for selecting COVID-19 convalescent plasma

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated that coronavirus disease 2019 (COVID-19) convalescent plasmas (CCPs) with low neutralizing and high fragment crystallizable (Fc)-effector activity result in effective prophylaxis.

15 Jun 2022

Immunity conferred by COVID-19 vaccines in solid organ transplant recipients

In a recent study posted to the medRxiv* preprint server, researchers estimated the humoral immunity imparted by the two/three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in solid organ transplant recipients (SOTRs).

18 May 2022

Review aims to deepen the understanding of the role of natural killer cells in COVID-19

In a recent study published in Biomedicines, researchers explored the utility of natural killer (NK) cells in coronavirus disease 2019 (COVID-19).

28 Apr 2022